HALO - Halozyme Therapeutics
$38.57 0.11 (0.29%)
Updated: 13:06 Apr 28, 2024 ESTNext Hour's AI Forecast
N/A
Avg. Accuracy (AI)
N/A
Next Session's AI Forecast
N/A
Avg. Accuracy (AI)
N/A
Next Week's AI Forecast
N/A
Trend's Accuracy (AI)
N/A
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0 | -0.16 | 0.16 | 0.03 | 0.05 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0 | 0.84 | 1.27 | 1.57 | 1.68 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | N/A | N/A | 50.33% | 53.76% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 0 | -100% | 38.77 | -1.85% | 39.5 | 4.11% | 37.94 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.81 | 51.22 | 0.59 | 44.75 |
|---|
Halozyme Therapeutics Technical Analysis News
News About Halozyme Therapeutics in last three days
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
At May 7, 2024, 10:00 pm
Zacks
Mentions in the news over the last three days
In the last three days Halozyme Therapeutics was mentioned 2 times in 1 different publications.
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
"For the quarter ended March 2024, Halozyme Therapeutics (HALO Quick QuoteHALO - Free Report) reported revenue of $195.88 million, up 20.8% over the same period last year. EPS came in at $0.79, compared to $0.47 in the year-ago quarter.", "Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
At May 7, 2024, 10:00 pm
Zacks
Halozyme Therapeutics
12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889
https://halozyme.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 393 |
Description
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Corporate Governance
Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of January 28, 2024 is 2. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 3; Compensation: 2.
List of holders with stock participation in Halozyme Therapeutics.
| Holder Rank | Holder | Shares | Date Reported | % Out | Value |
|---|